Cronos Australia Ltd. (VIT) AI Stock Analysis

• Market Cap: AU$37.78M
• Dividend Yield: 3.28%
• Average Volume (3M): 228.84K
• Price to Earnings (P/E): 10.6
• Beta (1Y): 1.86
• Revenue Growth: 0.13%
• EPS Growth: -12.90%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): <0.01
• Shares Outstanding: 662,741,800
• 10 Day Avg. Volume: 238,134
• 30 Day Avg. Volume: 228,844
• PEG Ratio: -1.01
• Price to Book (P/B): 0.78
• Price to Sales (P/S): 0.30
• P/FCF Ratio: 14.63
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 59 Neutral
• Price Target: AU$0.06 ▲(1.67% Upside)

Cronos Australia Ltd.'s overall stock score is primarily influenced by its stable financial position and attractive valuation. However, the bearish technical indicators and challenges in revenue growth and cash generation weigh down the score. The absence of recent earnings call insights or notable corporate events means these factors do not impact the score.

Positive Factors

Conservative Leverage

A low debt-to-equity ratio (0.25) indicates conservative leverage, preserving financial flexibility and lowering default risk. Over the next several months this supports capacity to fund operations, absorb shocks, or pursue selective investments without immediate refinancing pressure.

Strong Equity Base

A high equity ratio (63.85%) provides a durable capital buffer, improving solvency and supporting long-term R&D, regulatory compliance, or product launches typical in specialty drug makers. This structural strength reduces bankruptcy risk and aids strategic flexibility over months.

Stable Gross Margin

A stable gross margin (~27.2%) shows sustained control of production and direct costs, helping preserve core profitability despite revenue variability. This margin resilience supports long-term margin sustainability and the ability to fund SG&A or product development without immediate margin erosion.

Negative Factors

Severe Free Cash Flow Decline

An extreme drop in free cash flow growth (‑2056%) signals acute cash generation problems. This undermines the firm's ability to self-fund operations, capex, dividends or pay down debt, increasing reliance on external financing and raising structural liquidity risk over the next several months.

Poor Cash Conversion

A low operating cash flow to net income ratio (0.14) means accounting profits are not converting into cash. This weak cash conversion exacerbates working capital strain, limits reinvestment capacity, and creates persistent liquidity pressure that can impair strategic initiatives in the medium term.

Earnings Pressure and Low Margins

Negative EPS growth (~-12.9%) alongside modest net profit margins (2.68%) and low EBIT/EBITDA margins point to constrained earnings power. This reduces retained earnings for reinvestment, limits resilience to cost inflation, and may slow growth initiatives over the coming months.

Cronos Australia Ltd. Business Overview & Revenue Model

Company Description

Vitura Health Limited engages in the sale and distribution of medicinal cannabis products in Australia and Asia. Its brands include CanView, Burleigh Heads Cannabis, CDA Clinics, Cannadoc, and Adaya. The company was formerly known as Cronos Australia Limited and changed its name to Vitura Health Limited in February 2023. The company was incorporated in 2018 and is based in South Yarra, Australia.

How the Company Makes Money

Cronos Australia Ltd. generates revenue primarily through the sale of cannabis products, including dried flower, oils, and other derivatives that are marketed to both medicinal and recreational users. The company has established a revenue model that includes direct sales to consumers via dispensaries, partnerships with licensed retailers, and potential export opportunities in international markets. Key revenue streams include wholesale distribution to pharmacies and health practitioners, as well as direct consumer sales through online platforms. Additionally, strategic partnerships with other companies in the cannabis ecosystem, such as cultivation technology firms and research institutions, enhance its product offerings and market reach, contributing to its overall earnings.

Cronos Australia Ltd. Financial Statement Overview

Summary

Cronos Australia Ltd. demonstrates a stable financial position with moderate profitability and a strong equity base. However, the company faces challenges in revenue growth and cash generation, which could impact its future financial performance. The balance sheet remains strong with manageable debt levels, but there is room for improvement in operational efficiency and cash flow management to enhance overall financial health.

Income Statement

Cronos Australia Ltd. has shown a mixed performance in its income statement. The company has experienced a slight decline in revenue growth recently, with a negative growth rate of -2.001% in the latest period. However, the gross profit margin remains relatively stable at 27.21%, indicating efficient cost management. The net profit margin is modest at 2.68%, reflecting some profitability but also highlighting potential challenges in converting revenue into net income. The EBIT and EBITDA margins are low, suggesting limited operational efficiency. Overall, the income statement reflects moderate profitability with room for improvement in revenue growth and operational efficiency.

Balance Sheet

The balance sheet of Cronos Australia Ltd. indicates a stable financial position with a debt-to-equity ratio of 0.25, suggesting a conservative approach to leverage. The return on equity is 6.90%, which is moderate and indicates some efficiency in generating returns for shareholders. The equity ratio stands at 63.85%, showing a strong equity base relative to total assets. Overall, the balance sheet reflects a stable financial structure with manageable debt levels and a solid equity position, although there is potential for enhancing shareholder returns.

Cash Flow

The cash flow statement reveals challenges in cash generation, with a significant decline in free cash flow growth at -2056.03%. The operating cash flow to net income ratio is low at 0.14, indicating limited cash conversion from net income. However, the free cash flow to net income ratio is relatively high at 0.97, suggesting that the company is able to convert a substantial portion of its net income into free cash flow. Overall, the cash flow position highlights potential liquidity concerns and the need for improved cash generation capabilities.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	124.04M	124.04M	123.87M	117.34M	66.99M	21.71M
Gross Profit	33.75M	33.75M	34.22M	25.96M	25.43M	3.19M
EBITDA	5.64M	5.64M	7.08M	21.08M	10.87M	2.12M
Net Income	3.32M	3.32M	3.51M	13.81M	6.05M	-4.05M
Balance Sheet
Total Assets	75.49M	75.49M	71.28M	46.90M	42.87M	12.69M
Cash, Cash Equivalents and Short-Term Investments	7.58M	7.58M	11.35M	18.85M	16.08M	9.47M
Total Debt	11.97M	11.97M	11.02M	1.71M	5.06M	718.02K
Total Liabilities	27.89M	27.89M	32.84M	11.99M	16.79M	3.47M
Stockholders Equity	48.20M	48.20M	38.78M	34.98M	26.10M	9.30M
Cash Flow
Free Cash Flow	2.58M	2.58M	6.21M	8.78M	13.13M	1.01M
Operating Cash Flow	2.67M	2.67M	7.00M	9.71M	13.50M	1.07M
Investing Cash Flow	-13.87M	-13.87M	-13.20M	-837.72K	2.00M	-160.69K
Financing Cash Flow	7.43M	7.43M	-1.30M	-6.10M	-1.50M	-262.03K

Cronos Australia Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VIT, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.54 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:VIT.

Cronos Australia Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIT	59 Neutral	AU$37.78M	10.56	7.64%	3.28%	0.13%	-12.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EXL	49 Neutral	AU$4.14M	-1.09	-26.84%	―	36.60%	85.28%
EPN	46 Neutral	AU$11.37M	-1.79	-469.43%	―	-1.25%	-188.33%
CAN	39 Underperform	AU$12.71M	-0.24	-401.36%	―	-26.49%	61.72%

Cronos Australia Ltd. Corporate Events

Vitura Health Cancels Over 2.3 Million Unvested Performance Rights

Vitura Health Limited has notified the market that 2,316,848 performance rights have lapsed after the conditions attached to those rights were not met or became incapable of being satisfied, effective 28 January 2026. The cessation of these securities reduces the company’s pool of potential future equity dilution, providing greater clarity for existing shareholders regarding the current capital structure, although it may also signal that certain performance or strategic milestones underpinning these rights were not achieved.

The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.

Vitura Health Accelerates Leadership Reshuffle to Drive Next Phase of Transformation

Vitura Health has announced the immediate departure of CEO Geoff Cockerill as the board seeks leadership better aligned with its push for improved financial and operational performance and the next phase of its transformation. Chief Revenue Officer Ryan Tattle will oversee day-to-day operations as interim leader, with all executive team members reporting to him, while non-executive director Shane Tanner steps into an Interim Executive Director role to support execution of performance improvement initiatives until at least 30 April 2026. The board has begun an advanced search for a new, execution-focused CEO, and confirmed that incoming CFO Andrew Cook, who brings more than two decades of senior international finance experience, will join the business earlier than expected on 9 February 2026. Chair Robert Iervasi said the company’s strategic priorities remain unchanged, emphasising operational excellence, financial discipline and consolidation of Vitura’s position as a trusted healthcare services provider, signalling continuity of strategy despite the top leadership reshuffle.

The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.

Vitura Health Announces Lapse of 1.9 Million Performance Rights

Vitura Health Limited has notified the market that 1,931,081 performance rights have lapsed because the conditions attached to those rights were not, or could no longer be, satisfied. The cessation of these conditional securities reduces the pool of potential equity issuance, which may slightly affect future dilution outcomes for existing shareholders but does not change the company’s outstanding ordinary share capital.

The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.

Vitura Health Names Andrew Cook as New Chief Financial Officer

Vitura Health Limited has appointed experienced finance executive Andrew Cook as its new Chief Financial Officer, with the Queensland-based Chartered Accountant expected to commence in the role in the third quarter of FY2026. With more than two decades of senior finance experience across major organisations including Energy Queensland, Origin Energy, SABMiller and most recently as CFO and Company Secretary of AnteoTech Limited, Cook is expected to strengthen Vitura’s financial leadership as it pursues its strategic priorities in digital health, medicinal cannabis distribution and psychedelic therapies, supporting the company’s efforts to scale its integrated health platforms and deliver long-term value to shareholders.

The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.

Vitura Health Lodges Amended Constitution After Administrative Delay

Vitura Health Limited has lodged its amended company constitution with the ASX, formalising changes approved by shareholders at the company’s 26 November 2025 Annual General Meeting, after a delay attributed to an administrative oversight. While the filing itself is procedural, it completes the governance step endorsed by investors and underscores the company’s efforts to align its corporate framework with its evolving digital health and medicinal products platform, which spans medicinal cannabis distribution, telehealth services, and a growing foothold in regulated psychedelic therapies, potentially strengthening its position in Australia’s rapidly developing digital and specialty healthcare markets.

The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.

Vitura Health Options Lapse, Removing 4.5 Million Potential Shares

Vitura Health Limited has announced the cessation of 4.5 million unexercised options after their expiry on 16 December 2025, comprising three tranches of 1.5 million options each with exercise prices of $0.27, $0.34 and $0.41. The lapse of these options, which expired without being converted into shares, slightly simplifies Vitura Health’s capital structure and removes a potential source of future equity dilution for existing shareholders.

The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.

Vitura Health Flags Isolated Late Lodgement of Director Interest Notice

Vitura Health Limited has disclosed a late lodgement of an Appendix 3Y notice relating to director Gerard Fogarty’s participation in the company’s dividend reinvestment plan, after an administrative oversight meant the securities issued on 30 September 2025 were not reported at the time. The company said the notice was filed promptly once the error was identified, described the incident as isolated, and reaffirmed that its existing reporting and notification processes remain adequate to ensure compliance with ASX director disclosure rules, signalling limited operational or governance impact for shareholders and other stakeholders.

The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.

Vitura Health Appoints Michael Sapountzis as New Company Secretary

Vitura Health Limited announced the appointment of Michael Sapountzis as its new Company Secretary, replacing Tom Howitt, who will remain as Chief Financial Officer until January 12, 2026. This leadership change aligns with Vitura’s operational priorities as it continues to advance its presence in the digital healthcare and medicinal cannabis markets. The move strengthens governance and administrative functions, positioning the company for future growth in its integrated healthcare systems.

The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.

Vitura Health Establishes Industry Advisory Group to Boost Clinical Governance

Vitura Health Limited has announced the formation of an Industry Advisory Group to enhance its clinical governance and patient experiences. Chaired by Gerard Fogarty, the group will advise on medical practice management and emerging opportunities in the medicinal cannabis and specialty clinics industry, aiming to maintain industry-leading standards and improve patient outcomes.

The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.

Vitura Health Advances Digital Health Strategy at 2025 AGM

Vitura Health Limited held its 2025 Annual General Meeting, where three resolutions were passed, and one was withdrawn. The meeting highlighted the company’s strategic focus on expanding its digital health platform and integrating new opportunities such as psychedelic product distribution, reinforcing its position in the medicinal cannabis and telehealth markets.

Vitura Health Unveils Strategic Expansion at 2025 AGM

Vitura Health Limited announced the presentation for its 2025 Annual General Meeting, highlighting its ongoing efforts to expand its digital health platform and product distribution capabilities. The company’s strategic initiatives, including its joint venture for psychedelic products and the integration of telehealth services, position it as a significant player in the evolving healthcare market, potentially impacting stakeholders by broadening access to innovative health solutions.

Vitura Health Withdraws Resolution Ahead of AGM

Vitura Health Limited has announced the withdrawal of Resolution 3, concerning the ratification of shares issued to AFO Investments Pty Ltd, ahead of its 2025 Annual General Meeting. This decision may impact shareholder expectations and reflects the company’s strategic considerations in its ongoing operations and market positioning.